279 related articles for article (PubMed ID: 28942551)
1. Androgen excess and metabolic disorders in women with PCOS: beyond the body mass index.
Condorelli RA; Calogero AE; Di Mauro M; Mongioi' LM; Cannarella R; Rosta G; La Vignera S
J Endocrinol Invest; 2018 Apr; 41(4):383-388. PubMed ID: 28942551
[TBL] [Abstract][Full Text] [Related]
2. Hyperandrogenism Accompanies Increased Intra-Abdominal Fat Storage in Normal Weight Polycystic Ovary Syndrome Women.
Dumesic DA; Akopians AL; Madrigal VK; Ramirez E; Margolis DJ; Sarma MK; Thomas AM; Grogan TR; Haykal R; Schooler TA; Okeya BL; Abbott DH; Chazenbalk GD
J Clin Endocrinol Metab; 2016 Nov; 101(11):4178-4188. PubMed ID: 27571186
[TBL] [Abstract][Full Text] [Related]
3. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.
Sanchez-Garrido MA; Tena-Sempere M
Mol Metab; 2020 May; 35():100937. PubMed ID: 32244180
[TBL] [Abstract][Full Text] [Related]
4. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
[TBL] [Abstract][Full Text] [Related]
5. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
Jeanes YM; Reeves S
Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
[TBL] [Abstract][Full Text] [Related]
6. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease.
Kim JJ; Kim D; Yim JY; Kang JH; Han KH; Kim SM; Hwang KR; Ku SY; Suh CS; Kim SH; Choi YM
Aliment Pharmacol Ther; 2017 Jun; 45(11):1403-1412. PubMed ID: 28370150
[TBL] [Abstract][Full Text] [Related]
7. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.
Rocha ALL; Faria LC; Guimarães TCM; Moreira GV; Cândido AL; Couto CA; Reis FM
J Endocrinol Invest; 2017 Dec; 40(12):1279-1288. PubMed ID: 28612285
[TBL] [Abstract][Full Text] [Related]
8. Adipocyte and steroidogenic cell cross-talk in polycystic ovary syndrome.
de Medeiros SF; Rodgers RJ; Norman RJ
Hum Reprod Update; 2021 Jun; 27(4):771-796. PubMed ID: 33764457
[TBL] [Abstract][Full Text] [Related]
9. Adipocyte fatty acid-binding protein is associated with markers of obesity, but is an unlikely link between obesity, insulin resistance, and hyperandrogenism in polycystic ovary syndrome women.
Möhlig M; Weickert MO; Ghadamgadai E; Machlitt A; Pfüller B; Arafat AM; Pfeiffer AF; Schöfl C
Eur J Endocrinol; 2007 Aug; 157(2):195-200. PubMed ID: 17656598
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Paschou SA; Polyzos SA; Anagnostis P; Goulis DG; Kanaka-Gantenbein C; Lambrinoudaki I; Georgopoulos NA; Vryonidou A
Endocrine; 2020 Jan; 67(1):1-8. PubMed ID: 31538291
[TBL] [Abstract][Full Text] [Related]
11. Accelerated subcutaneous abdominal stem cell adipogenesis predicts insulin sensitivity in normal-weight women with polycystic ovary syndrome.
Dumesic DA; Tulberg A; Leung KL; Fisch SC; Grogan TR; Abbott DH; Naik R; Chazenbalk GD
Fertil Steril; 2021 Jul; 116(1):232-242. PubMed ID: 33341231
[TBL] [Abstract][Full Text] [Related]
12. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study.
Puurunen J; Piltonen T; Puukka K; Ruokonen A; Savolainen MJ; Bloigu R; Morin-Papunen L; Tapanainen JS
J Clin Endocrinol Metab; 2013 Dec; 98(12):4798-807. PubMed ID: 24152688
[TBL] [Abstract][Full Text] [Related]
13. Polycystic ovary syndrome as a plausible evolutionary outcome of metabolic adaptation.
Dumesic DA; Padmanabhan V; Chazenbalk GD; Abbott DH
Reprod Biol Endocrinol; 2022 Jan; 20(1):12. PubMed ID: 35012577
[TBL] [Abstract][Full Text] [Related]
14. Visceral adiposity index as a predictor of clinical severity and therapeutic outcome of PCOS.
Zheng SH; Li XL
Gynecol Endocrinol; 2016; 32(3):177-83. PubMed ID: 26502288
[TBL] [Abstract][Full Text] [Related]
15. Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome.
Alpañés M; Luque-Ramírez M; Martínez-García MÁ; Fernández-Durán E; Álvarez-Blasco F; Escobar-Morreale HF
Fertil Steril; 2015 Mar; 103(3):795-801.e2. PubMed ID: 25585504
[TBL] [Abstract][Full Text] [Related]
16. Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome.
Dumesic DA; Winnett C; Lu G; Grogan TR; Abbott DH; Naik R; Chazenbalk GD
Fertil Steril; 2023 Jan; 119(1):116-126. PubMed ID: 36400597
[TBL] [Abstract][Full Text] [Related]
17. Precocious subcutaneous abdominal stem cell development to adipocytes in normal-weight women with polycystic ovary syndrome.
Fisch SC; Nikou AF; Wright EA; Phan JD; Leung KL; Grogan TR; Abbott DH; Chazenbalk GD; Dumesic DA
Fertil Steril; 2018 Dec; 110(7):1367-1376. PubMed ID: 30503136
[TBL] [Abstract][Full Text] [Related]
18. Metabolic inflexibility is a feature of women with polycystic ovary syndrome and is associated with both insulin resistance and hyperandrogenism.
Di Sarra D; Tosi F; Bonin C; Fiers T; Kaufman JM; Signori C; Zambotti F; Dall'Alda M; Caruso B; Zanolin ME; Bonora E; Moghetti P
J Clin Endocrinol Metab; 2013 Jun; 98(6):2581-8. PubMed ID: 23596136
[TBL] [Abstract][Full Text] [Related]
19. Development of obesity and polycystic ovary syndrome in adolescents.
Vilmann LS; Thisted E; Baker JL; Holm JC
Horm Res Paediatr; 2012; 78(5-6):269-78. PubMed ID: 23208318
[TBL] [Abstract][Full Text] [Related]
20. Polycystic ovary syndrome and metabolic syndrome.
Ali AT
Ceska Gynekol; 2015 Aug; 80(4):279-89. PubMed ID: 26265416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
